Palau

Medicines oversight and public-health functions in Palau are administered through the Ministry of Health and Human Services. The Ministry’s health services and pharmaceutical functions provide the practical route for addressing medicine-safety concerns, while international safety-system status can be checked against the WHO Programme for International Drug Monitoring. Publicly available Palauan sources do not currently publish a detailed, industry-facing pharmacovigilance framework establishing blanket requirements for every marketing authorisation Holder (MAH) to appoint a resident QPPV, maintain a local PSMF, or submit ICSRs and periodic safety reports to fixed national timelines. Companies importing or supplying medicines should therefore confirm product- and authorisation-specific expectations with the Ministry, maintain a documented global safety system, designate an accessible local safety contact, and preserve procedures for collecting and assessing adverse events, product-quality complaints, medication errors, recalls, and emerging safety signals. Any significant risk or urgent safety action should be communicated promptly through the applicable Ministry or public-health channel. BAUPHARMA supporting resources (operational context only, not national regulatory evidence): Effective Signal Management in Pharmacovigilance.